Program Book

Recommendations

Info

2028 RF19 RAPID REGRESSION OF POST-BRACHYTHERAPY CHOROIDAL MELANOMA IN RESPONSE TO INTRAVITREAL AVASTIN Peter Hovland MD PhD (peterhovland@gmail.com) Colorado Retina Associates, Denver CO Purpose. To describe the rapid decrease in tumor volume seen in a patient treated with intravitreal avastin following brachytherapy. Methods. A 65 year old woman with anteriorly located choroidal melanoma of 10 mm thickness was treated with I-125 brachytherapy. After 6 months, persistent symptomatic sub-retinal fluid was treated with intravitreal avastin. Tumor thickness was monitored by b-scan ultrasound. Results. FNAB analysis of the tumor confirmed it to be a melanoma with a GEP Class 1. Tumor volume gradually reduced from a pre-treatment 10.3 thickness to 8.0 mm in the first 6 months. Following 2 injections of intravitreal avastin, the tumor thickness decreased to less than 1 mm. Conclusions. Intravitreal avastin injections were associated with a rapid decrease in tumor volume in a patient with a large choroidal melanoma post-brachytherapy. Financial disclosure. None 1845 RF20 LIGHT AND ELECTRON MICROSCOPY OF TWO CILIARY BODY TUMORS L. Schoenfield, J. McMahon, A. Singh (schoenl@ccf.org) Cleveland Clinic Purpose. To discuss the differential diagnosis of two ciliary body tumors. Methods. Two cases of ciliary body tumors were evaluated with routine H&E stains, immunoperoxidase stains, and electron microscopy. Results. To be discussed at rapid fire section. Conclusions. Two tumors from the ciliary body of a 70 year old male and a 77 year old female will be presented with light microscopy (including immunoperoxidase stains) and electron microscopy. Discussion and opinions from the audience will be welcomed as to the nature of these lesions. Financial disclosure. None 513 RF21 RETINAL DETACHMENT AFTER TTT FOR ACTIVE CHOROIDAL MELANOMA Prithvi Mruthyunjaya, MD (mruth001@mc.duke.edu) Ocular Oncology and Vitreoretinal Surgery Services, Duke Eye Center, Durham, NC Purpose. 54 yo male with choroidal melanoma and exudative retinal detachment has undergone plaque brachytherapy with continued growth. Transpupillary thermotherapy is applied and a subsequent rhegmatogenous retinal detachment develops. What is the ideal timing of RD repair in the setting of an active melanoma? Methods. Case report Results. Audience participation requested Conclusions. What is the ideal timing of RD repair in the setting of an Rapid Fire Cases Abstracts 78 active melanoma? Financial disclosure. None 55 RF22 TREATMENT OF DIFFUSE IRIS MELANOMA B. Damato (bertil.damato@gmail.com) Liverpool, UK. Purpose. Succesfull treatment of diffuse iris melanoma after proton beam radiotherapy of the entire anterior segment Financial disclosure. None 62 RF23 LATE RECURRENCE OF A PRESUMED IRIS MELANO- MA John McWhae, Ryan Steinke (jmcwhae@gmail.com) Purpose. A 65-year old woman presented with a spontaneous hyphema OD. She has a history of iris melanoma treated with iridectomy 35 years prior. She was found to have 5 small amelanotic angle lesions. The patient refused any interventions. A second hyphema occurred 3 years later. The patient has now been followed for 5 years without any growth of the lesions. Possible explanations for this unusual tumor behaviour will be discussed. Financial disclosure. None 45 RF24 HOLY TUMOR Carol Shields, M.D. (carol.shields@shieldsoncology.com) Wills Eye Institute Purpose. An interesting case. Methods. Patient with uveal melanoma. Results. Halo nevi developed. Conclusions. An interesting cutaneous phenomenon developed following treatment of uveal melanoma in a young woman. Financial disclosure. None 1848 RF25 RESECTION OF AN IRIS TUMOR Arun D Singh, Laura Snyder, Linda Brodell, Mary B. Turell (singha@ccf.org) Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, OH Purpose. A 71-year old Caucasian female was noted to have a small, light brown mass extending into the angle without iris deformity. On follow up examination sixteen months later, a new finding of iris distortion was observed. Financial disclosure. None 410 RF26 MELANOMA OR MELANOCYTOMA?
Arturo Irarrazaval, Pablo Cazon, Oscar Croxatto (artuira@consultoresoftalmologicos.com) Consultores Oftalmologicos Purpose. To show an unusual evolution of a plaque treated tumor of the posterior pole. Methods. A patient treated with plaque for a mushroom shaped choroidal melanoma, with characteristic ecography, that had quick growth after some years of stability, even after TTT adjuvant treatment. Results. The pathology of enucleated eye shows that the tumor was a melanocytoma Conclusions. A choroidal melanocytoma may have an unusual form of presentation and evolution. Financial disclosure None 1655 RF27 MALIGNANT TRANSFORMATION OF CELLULAR BLUE NEVUS IN AN 8-YEAR-OLD GIRL A P Moulin1, M Hamedani1, A Oberic1, M Mihm2, F Jakobiec3, V Prieto4, JN Myers4, F Demont4, RJ Skoracki4, S Woodman4, B Eemaeli4. (alexandre. moulin@fa2.ch) 1. Jules Gonin Eye Hospital, Lausanne University, Switzerland 2. Brigham and Women’s Hospital, Harvard Medical School, Boston 3. Massachussetts Eye and Ear Infirmary, Harvard Medical School, Boston 4. MD Anderson Cancer Center, University of Texas, Houston Purpose. To report a case of malignant transformation of blue nevus of eyelid into melanoma of orbit in an 8-year-old girl. Methods. Observational case report. Results. An 8-year-old girl was referred to Jules Gonin Eye Hospital for evaluation of an extensive blue nevus involving the right lower eyelid, the inferior conjunctiva and the orbit with evidence of recent growth into the orbit. Multiple palpebral and orbital biopsies were performed. The deepest lesions were consistent with cellular blue nevus with severe atypia. After 6 months observation, growth of the orbital mass led to repeat biopsies which confirmed transformation into invasive melanoma in the orbit. aCGH demonstrated a complete gain of chromosome 6. There were no mutations of BRAF (exon 15), GNAQ and GNA11 (exons 5). The patient was referred for evaluation and management to the University of Texas M.D. Anderson Cancer Center. The orbital tumor was found to involve the pterygopalatine fossa and other skull base structures. A multidisciplinary procedure including an orbital exenteration and skull base surgery was performed followed 4 weeks later by proton radiotherapy. Histopathology revealed atypical cellular blue nevus with foci of melanoma in the posterior orbit. Conclusions. Cellular blue nevi can rarely transform into malignant melanoma and can involve deeper structures in the orbital apex and skull base. To our knowledge, this may be the youngest patient to date documented to have a malignant transformation of cellular blue nevus into melanoma. The extent of involvement of atypical blue nevus required a complex multidisciplinary surgical approach followed by high-dose radiation therapy. Financial disclosure. None Rapid Fire Cases Abstracts 79 1618 RF28 ORBITAL MELANOMA AND NAEVUS OF OTA Victoria M.L. Cohen (victoria.lendrum@gmail.com) Ocular Oncology Service, Moorfields and St Batholomew’s Hospital London, UK. Purpose. To report the management of an extensive orbital melanoma in a patient with naevus of Ota Methods. A 46-year old male with long standing pigmentation of the eye and eyelid presented with progressive proptosis. Orbital biopsy confirmed the presence of melanoma. Despite adjuvant radiotherapy, the lesion continued to enlarge. The subsequent radical surgical approach is described Results. Melanoma was found to be infiltrating the orbital bone, maxilla, nasopharynx and dura mata. Conclusions. Orbital and cerebral melanoma is very rare but the most lethal association of naevus of Ota. Financial disclosure. None 558 RF29 MANAGEMENT OF A RARE ADNEXAL TUMOR Sonul Mehta, MD1, John Harvey, MD, F.R.C.S.2 (sonulmehta@gmail. com) 1. Division of Oculoplastics and Orbital Surgery, Department of Ophthalmology and Visual Sciences, University of Toronto 2. Division of Oculoplastics and Orbital Surgery, Department of Ophthalmology and Visual Sciences, McMaster University Purpose. A 28 year old male who sustained a right upper brow and eyelid laceration after an injury that presented with a non-healing wound 3 months later. He was found to have a rare adnexal tumor. He will be presented to the audience as an unknown for opinions on management. Methods. Case Study Results. He was found to have a rare adnexal tumor that has failed multiple reconstructions and found to have recurrence of tumor. Conclusions. He will be presented to the audience as an unknown for opinions on management. Financial disclosure. None 19 RF30 AMELANOTIC CONJUNCTIVAL TUMOR - MALIGNANT OR BENIGN? Priscilla Ballalai, Maria C. Martins, Marcia Lowen (pbbordon@terra.com.br) Federal University of Sao Paulo Purpose. 82 yo female with a rapid growing conjunctival tumor Financial disclosure. None 1809 RF31 65-YEAR OLD WOMAN WITH DIFFUSE CONJUNCTIVAL NEOPLASM J. William Harbour, MD (harbour@vision.wustl.edu)
Page 1 and 2:
XV th NH City Hotel and Tower Boliv
Page 3 and 4:
List of Congress Meetings of the In
Page 5:
Table of Contents Welcome address K
Page 8 and 9:
Keynote Lectures Lymphoma of the oc
Page 10 and 11:
The venue for the Biannual Meeting
Page 12 and 13:
Buenos Aires Downtown MAP 12 Venue
Page 15 and 16:
MORNING 8.30-10.10 Papers (Moderato
Page 17 and 18:
50 RES 26 USING THE GLYCOLYTIC INHI
Page 19 and 20:
2226 RES 4 NOTCH SIGNALING PROMOTES
Page 21 and 22:
a reduction in the number of living
Page 23 and 24:
array further detected copy number
Page 25 and 26:
615 RES 21 TRB2 AND SKP2 IN THE RET
Page 27: following treatment with 2-fluorode
Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
Page 32 and 33: Posters Retinoblastoma 2006 RBp100
Page 34 and 35: 120 RBp135 MANAGEMENT OF AN ECTOPIC
Page 36 and 37: After treatment, 10 patients lived
Page 38 and 39: Methods. Six cycles of carboplatin
Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
Page 42 and 43: 4. Fluoroscopy for cannula placemen
Page 44 and 45: Methods. A retrospective chart revi
Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
Page 50 and 51: months. Mean delay between beginnin
Page 52 and 53: not associated with severity of RB.
Page 54 and 55: Conclusions. During a ten-year peri
Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
Page 58 and 59: (follow-up 5 years). Two years afte
Page 61 and 62: 8.30-9.00 Poster presentations ECOp
Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
Page 65 and 66: Morning 8.30-9.00 Poster presentati
Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
Page 69 and 70: Purpose. Ocular surface squamous ne
Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
Page 73 and 74: of the tissues most commonly affect
Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
Page 77: Ocular Oncology Service, St Barthol
Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
Page 85 and 86: patients. The isolated involvement
Page 87 and 88: exudative fluid from the hemangioma
Page 89: maximum of 7 rituximab injections.
Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
Page 94 and 95: 8.30-9.00 Poster presentations UMp1
Page 96 and 97: 2253 UM1 PRELIMINARY STUDY OF VASCU
Page 98 and 99: Purpose. To determine the presence
Page 100 and 101: gene expression profile of melanocy
Page 102 and 103: the rarity of UM, timely completion
Page 104 and 105: C. Metz, T. Gkika, W. Sauerwein, N.
Page 106 and 107: Patients in the triamcinolone group
Page 108 and 109: 1350 Ump101 INDUCED EXPRESSION OF P
Page 110 and 111: Purpose. To report the Results of R
Page 112 and 113: 1547 Ump113 LONG-TERM OBSERVATIONS
Page 114 and 115: 2038 Ump119 VALUE OF DOPPLER ANALYS
Page 116: Methods. A total of 4070 patients w
Page 119: First authors Naseripour, Masood No
show all

Program Book

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?